Human immunodeficiency virus-uninfected adults with newly diagnosed smear-positive pulmonary tuberculosis were randomized to receive a 3 - or 4-month moxifloxacin regimen ( moxifloxacin [ M ] , isoniazid [ H ] , rifampicin [ R ] , pyrazinamide [ Z ] , ethambutol [ E ] ) or the control regimen ( RHZE thrice weekly ) .